KRTAP10-2: A Potential Drug Target and Biomarker (G386679)

Target Name: KRTAP10-2

NCBI ID: G386679

KRTAP10-2

KRTAP10-2: A Potential Drug Target and Biomarker

KRTAP10-2, also known as KRTAP18.2, is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and kidneys. It is a member of the KRTAP gene family, which is known for its role in regulating the transport of proteins across cell membranes. KRTAP10-2 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues.

The KRTAP10-2 protein is composed of 115 amino acid residues and has a calculated molecular weight of 13.9 kDa. It has a unique N-terminal region that consists of a single amino acid residue, a hydrophobic region, and a C-terminal region that contains a conserved glycine loop and a putative transmembrane domain. The C-terminal region of KRTAP10-2 is rich in hydrophobic residues, which is expected to interact with membrane lipids and influence the protein's localization and stability.

KRTAP10-2 is expressed in various tissues of the body, including the brain, lungs, heart, and kidneys, and has been shown to localize to the endoplasmic reticulum (ER) and the transmembrane space of various cell types. It has also been shown to interact with several protein partners, including the transmembrane protein TRPV4 and the cytoplasmic protein TSPO6.

KRTAP10-2 has been identified as a potential drug target due to its unique structure and expression pattern. Its unique N-terminal region and C-terminal region, rich in hydrophobic residues, make it an attractive target for small molecules or antibodies that can modulate its localization and activity. Additionally, its expression pattern in various tissues and its interaction with several protein partners make it a promising biomarker for the diagnosis and monitoring of various diseases.

In addition to its potential as a drug target, KRTAP10-2 has also been identified as a biomarker for several diseases. Its expression has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and respiratory diseases. Additionally, its expression has been shown to be increased in certain diseases, such as heart failure and Chronic Obstructive Pulmonary Disease (COPD), which may indicate its potential as a diagnostic biomarker or target for these diseases.

In conclusion, KRTAP10-2 is a unique protein that has been identified as a potential drug target and biomarker due to its unique structure and expression pattern. Its N-terminal and C-terminal regions, rich in hydrophobic residues, make it an attractive target for small molecules or antibodies that can modulate its localization and activity. Additionally, its expression pattern in various tissues and its interaction with several protein partners make it a promising biomarker for the diagnosis and monitoring of various diseases. Further research is needed to fully understand the potential of KRTAP10-2 as a drug target and biomarker.

Protein Name: Keratin Associated Protein 10-2

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP10-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP10-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets